by Riley Nolan | Jul 4, 2022 | Events, Featured
The EpiVax team had a great time in Tokyo hosting the Westin Immunogenicity Seminar! Please see pictures from the event below. Stay tuned for dates/details for 2023! The EpiVax team is pleased to share a new date for the 14th Annual Westin Tokyo Seminar, Friday...
by Riley Nolan | Jun 10, 2022 | Featured, News
PROVIDENCE, RI, June 10, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National...
by Riley Nolan | Jun 8, 2022 | Featured, Recipes for Success - Vlog
On this installment of Recipes for Success, Annie and Katie sit down to talk with Meena Subramanyam, VP, Global Program Leader and Conditional T cell Engager Platform Lead at Takeda Oncology. Meena attended the EpiVax Women in Biotech Summit that we hosted in New York...
by Riley Nolan | May 26, 2022 | Featured, Thinking Out Loud -Blog
Monkeypox, Avian Influenza and Q Fever, Oh My! Before getting to other news, we share your sorrow and horror over the lives lost in Texas this week and agree that common sense gun legislation is long overdue in the USA. EpiVax team members are appalled and saddened...
by Riley Nolan | May 25, 2022 | Featured, News
PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration...